PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Survodutide

BI 456906

Classification: GLP-1/glucagon dual agonist

Mechanism: Dual GLP-1/glucagon receptor activation

Benefits: Weight loss ~19%; MASH/NAFLD resolution Phase 2

Evidence tier: Phase 3 · Availability: Investigational

Primary sources

  1. le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity — randomised, double-blind, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024. PMID 38330987

Loading interactive view…